Concepedia

Tommaso Caravita di Toritto

TC

Statistics

Publications

10

Citations

1K

H-Index

10

Active since

2000

Affiliations

Sapienza University of Rome(Current)

St. Eugenio Hospital

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

Fondazione IRCCS Istituto Nazionale dei Tumori

Sheba Medical Center

Tommaso Caravita di Toritto is an author at Sapienza University of Rome specializing in medicine, multiple myeloma, and multiple myeloma treatment.

Publications per year

2000–2022

10

Publications

10

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 384 citations · Full text

, , +17

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

Alessandra Larocca, Federica Cavallo, Sara Bringhen et al. · Blood · 2011 · 286 citations

, , +12

Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma

Alessandra Larocca, Francesca Bonello, Gianluca Gaïdano et al. · Blood · 2021 · 81 citations · Full text

, , +12

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

Massimo Offidani, Laura Corvatta, Laura Maracci et al. · Blood Cancer Journal · 2013 · 61 citations · Full text

, , +14

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis et al. · The Lancet Haematology · 2022 · 47 citations

, , +12

1–5 of 10